Kornimate/medical-research-clean huggingface dataset:
progesterone as luteal support in frozen ivf natural cycles

Conditions: Infertility; Embryo Transfer

Summary: the profet study aims to investigate if luteal phase support by vaginal progesterone, is superior to no luteal phase support, in terms of live birth rate per woman after a frozen embryo transfer (fet), in a natural cycle (nc) after in-vitro fertilization (ivf), and if 7 weeks of treatment is superior to 3 weeks duration.

vaginal progesterone supplementation is routine treatment after ivf with fresh embryo transfer, but it is uncertain whether vaginal progesterone after frozen embryo transfer in natural cycles is efficacious in terms of increasing the chance of a live birth. the profet study is a multicenter, open randomized, controlled trial planning to include 1800 women, intended to undergo a fet in a natural cycle. primary objectives are to investigate if luteal phase support by vaginal progesterone, is superior to no luteal phase support, in terms of live birth rate per woman after a frozen embryo transfer, in a natural cycle and if 7 weeks of treatment is superior to 3 weeks duration. secondary objectives are to compare groups regarding pregnancy outcomes including biochemical pregnancy, clinical, ongoing and term pregnancy rates, as well as rates of miscarriage, termination of pregnancy, and ectopic pregnancy. secondary objectives are also perinatal and obstetrics outcomes, self-reported side effects, adverse events and cost effectiveness. the investigators will also analyze the effect of s-progesterone level before fet on the chance of achieving live birth and secondary pregnancy outcomes.

Eligibility criteria:
inclusion criteria: * planned for a fet-nc with a blastocyst * bmi \>18.5 \<35 * regular menstrual cycles 24-35 days * given informed consent * understand written and spoken swedish, english or arabic exclusion criteria: * oocyte donor cycles, preimplantation genetic testing (pgt) cycles. uterine malformation, submucous myoma and endometrial polyps. * hypersensitivity against study medication. other contraindications according to www.fass.se * development of serious disease contraindicating art or pregnancy. * participation or recent participation in a clinical study with an investigational product (past 30 days). previous participation in this study.

Keywords: progesterone luteal phase support frozen embryo transfer natural cycles live birth
knowledge, practice and state of periodontal health

Conditions: Periodontal Diseases

Summary: the main objective of the study is to assess the knowledge and practice of periodontal health, which will be done using a well constructed and validated questionnaire. then periodontal health status of all participants will be assessed via clinical examination of certain teeth.

the primary outcome of the study is the knowledge of periodontal health.it will be assessed by 10 questions focusing on the basic knowledge of gingival appearance, causes and consequence of periodontal disease, impact of systemic disease on the progression of periodontal conditions, and prevention. then, periodontal practice will be addressed via several questions that evaluate the self-care practices of tooth brushing, flossing, mouth rinsing in recent one year, scaling in recent five years, and how to alleviate gingival bleeding if there is. periodontal examination using the community periodontal index (cpi) will be done for all of the participants to assess the status of periodontal condition. the dentition will be divided into sextants and the highest code number corresponding to the worst periodontal condition around each of the 10 indexed teeth being recorded.

Eligibility criteria:
inclusion criteria: 1. patients whose age is above 15 years old. 2. patient consulting in the outpatient clinic 3. provide informed consent. exclusion criteria: 1. patients having problem in opening their mouth or undergoing intermaxillary fixation where oral examination will not be possible. 2. patients diagnosed with psychiatric problems or intoxicated with alcohol or drugs.
effect of treatments in patients hospitalized for severe covid-19 pneumonia: a multicenter cohort study

Conditions: Covid-19; ARDS; Pneumonia

Summary: several treatments have been used in during the covid-19 pandemic of 2020. using patients' registries from several hospitals in paris, the investigators retrospectively analyzed associations between specific treatments, including but not limited to vaccines targeted against sars-cov-2, hydroxychloroquine, azithromycin, remdesivir, baricitinib, tocilizumab, sarilumab, lopinavir/ritonavir and oseltamivir; and clinical outcomes including, death and mechanical ventilation.

several treatments have been used in during the covid-19 pandemic of 2020. using patients' registries from several hospitals in paris, the investigators retrospectively analyzed associations between specific treatments, including but not limited to vaccines targeted against sars-cov-2, hydroxychloroquine, azithromycin, remdesivir, baricitinib, tocilizumab, sarilumab, lopinavir/ritonavir and oseltamivir; and clinical outcomes including, death and mechanical ventilation. other outcomes of interest include: acute kidney injury, encephalopathy, need for intensive care unit transfers.

Eligibility criteria:
inclusion criteria: * admitted for severe covid-19 pneumonia (i.e. requiring o2-support more than 6l/min with spo2\<96%) exclusion criteria: * patients who were previously in icu * patients already hospitalized prior to study start date * patients in palliative care * lack of consent
efficacy of octreotide acetate and cabergoline in patients with acromegaly

Conditions: Acromegaly

Summary: this study will investigate the efficacy of a combination treatment with octreotide acetate and cabergoline in acromegalic patients that are only partially responsive to a somatostatin analog monotherapy


Eligibility criteria:
inclusion criteria: * male and female patients (\> 18 years) with prior surgery of micro- or macroadenoma of the pituitary. * at least 6 months chronic treatment with 30mg octreotide (long acting release). * partial responsiveness, which is defined as follows: at any one point within the 6 months monotherapy with 30mg/month octreotide (long acting release) the patient must have experienced a decrease in gh and igf-1 of at least 25% as compared to pre-monotherapy values (= baseline). note: for efficacy analysis gh- and igf-1-values measured in the central laboratory at visit 1 (=study baseline) will be used. * lack of suppression of gh nadir to \< 1.0 µg/l, after oral administration of 75 g of glucose (ogtt) and igf-i levels at least 10% above the normal value ± 2 sd (adjusted for age and gender; brabant 2003) must be proven within 4 weeks prior to visit 1. however, if acromegaly symptoms are inadequately controlled as defined in the acromegaly comorbidities and symptom evaluation (as judged by the investigator), an abnormal gh or igf-1-value as defined above is sufficient. * patient's written informed consent. exclusion criteria: * requires surgery for recent significant deterioration in visual fields or other neurological signs, which are related to the pituitary tumor mass. * radiotherapy planned or radiotherapy for acromegaly within the last 2 years. * symptomatic cholelithiasis that is clinically relevant. * receiving treatment with dopamine agonists within the last 6 months or prior treatment with gh-receptor-antagonists. * patients with renal insufficiency, raynaud-syndrome or gastrointestinal ulcer/ bleeding cannot be included in the study or psychose in anamnesis. other protocol-defined inclusion/exclusion criteria may apply

Keywords: growth hormone (gh) igf-1 acromegaly pituitary adenoma brain tumor brain cancer octreotide acetate
a randomized study evaluating the feasibility and activity of three different combination with gemcitabine as first line therapy for non small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: phase ii study that will evaluate the activity of gemcitabine as intravesical therapy on the marker lesion in superficial bladder carcinoma at intermediate risk. primary objective is the evaluation of the pathological complete response after 8 instillation of gemcitabine. 46 patients are requested.


Eligibility criteria:
inclusion criteria * histologically or cytologically confirmed diagnosis of nsclc * patients must have a locoregionally advanced unresectable non metastatic nsclc stage iiib (only n3 supraclavicular or t4 for pleural effusion) or stage iv according to the revised international staging system * patients must have at least one measurable lesion * who performance status 0 or 1 * adequate organ function exclusion criteria: * prior systemic chemotherapy or immunotherapy including neoadjuvant or adjuvant treatments * prior radiotherapy for nsclc * patients with symptomatic brain metastases or with leptomeningeal disease. however, patients with symptomatic brain metastases who become asymptomatic under corticosteroids treatment can enter the study * current peripheral neuropathy nci grade 2
adapting mhealth technology to improve patient activation

Conditions: Spinal Cord Injuries; Stroke; Multiple Sclerosis

Summary: persons with disabilities (pwd) commonly experience fatigue, which often negatively impacts their everyday lives. management of this symptom can be challenging. satisfaction with current interventions to manage fatigue is low among pwd and there is a desire for more personalized approaches. the purpose of this study is to develop and test a fatigue self-management intervention using mobile phones that is personalized to each person's needs.

persons with disabilities (pwd) commonly experience fatigue, which adversely impacts their everyday lives. information to manage and improve fatigue can be complicated and overwhelming. little has been done to link mobile health (mhealth) approaches with patient activation and self-management to effectively address fatigue for pwd. the purpose of this study is to develop and pilot-test a fatigue self-management short message service (sms) text intervention using mobile phones to target patient activation levels in pwd. the proposed study will: (1) develop content for a fatigue self-management intervention using sms tailored to patient activation levels in persons with multiple sclerosis, spinal cord injury, and stroke. an advisory board made up of one physical medicine and rehabilitation physician and six pwd will provide input on the content and format for the developed content. (2) test the feasibility and acceptability of sms to improve patient activation for fatigue self-management in pwd. the long-term goal is to improve the health of pwd by increasing their skills, confidence, and knowledge to manage fatigue and other chronic symptoms that affect their daily life.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * had disability for at least one year * score of less than 10 on the modified fatigue impact scale 5 question (mfis-5) * ability to read and speak english at the 6th grade level * willing to use their own phone and sms exclusion criteria: * evidence of acute condition (e.g. relapse) * sleep apnea * inability to answer interview questions or provide consent * terminal cancer

Keywords: fatigue persons with disabilities patient activation mobile health
effects of neurodynamic mobilization and stretching exercises for chronic discogenic sciatica

Conditions: Physical Therapy

Summary: this study compares between neurodynamic mobilization and stretching exercises in treatment of chronic dicogenic sciatica

this study was conducted at the outpatient clinics, faculty of physical therapy, kafrelsheikh university to compare between the effects of slider, tensioner neurodynamic mobilization techniques and stretching exercises on pain, range of motion (rom) and functional disability for patients with chronic discogenic sciatica. design of the study: a pre-test post-test three-armed comparative study design was used for comparison between the effects of slider, tensioner neurodynamic mobilization techniques and stretching exercises for patients with chronic discogenic sciatica. selection of patients: sample size: using g-power software program and regarding f test study , alpha level of 0.05, confidence interval 95% and effect size of 0.25 (to detect small effects ), three groups and 6 dependent variables, the total sample size will be 36 patient (twelve in each group). to reach the specific sample size, forty-three patients were screened regarding the inclusion/exclusion criteria. thirty-six patient with unilateral chronic discogenic sciatica from both sexes (....male and ... female) were recruited from the outpatient clinics, faculty of physical therapy, kafrelsheikh university. their age ranged between 21-50 years. they were randomly allocated by simple random method; to avoid selection bias, patients were asked to choose a card of three wrapped cards representing the three treatment groups: group (a): received slider technique only. group (b): received tensioner technique only. group (c): received stretching exercises of back extensors, hamstrings and gastrocnemius muscles only.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed by magnetic resonance imaging (mri) confirming disc lesion. 2. radicular pain for at least twelve weeks up to one year with no acute episodes for the last four weeks. 3. positive slump test, with reproduction of neurological symptoms. 4. ages of 21-50 years of both sexes. 5. patients with functional disabilities e.g. during lifting or walking exclusion criteria: 1. patients with sciatica due to other pathologies e.g. lumbar canal stenosis or piriformis syndrome. 2. patients after any spinal surgery e.g. unilateral hemilaminectomy or microdiscectomy 3. negative slump test. 4. progressive neurological symptoms e.g. hyperirritable and unstable symptoms. 5. history of vertebral fracture or trauma. 6. systemic disorder e.g. diabetes mellitus. 7. pregnant women.
injection pressure & adductor canal block

Conditions: Orthopedic Disorders; Injury of Anterior Cruciate Ligament

Summary: this is a prospective, randomized, single-blinded human clinical trial that will examine how injection pressure influences the spread of a given volume of injectate in the adductor canal, during adductor canal nerve block.

this is a prospective, randomized, single-blinded human clinical trial that will examine how injection pressure influences the spread of a given volume of injectate in the adductor canal, during adductor canal nerve block. the study population will be patients undergoing elective anterior cruciate ligament repair in the distal lower extremity and receiving preoperative adductor canal nerve blocks for postoperative analgesia. they will be randomized into two groups of 25 patients each. the investigators speculate that high injection pressures (\>20 psi) will lead to greater spread of local anesthetic than low injection pressures (\<15 psi) during mid-thigh adductor canal nerve blocks. the primary endpoint is the spread of injectate, defined as the distance between the uppermost and lowermost limits of spread of local anesthetic as assessed by ultrasound. the secondary endpoints are the incidence of femoral and sciatic nerve blocks 30 minutes after block placement, amount of iv opioid administered intraoperatively and postoperatively, preoperative and postoperative pain (numeric rating scale, 0-10), and postoperative physical therapy milestone achievement.

Eligibility criteria:
inclusion criteria: 1. planned general anesthetic. 2. american society of anesthesia classes i, ii, or iii. 3. patients aged 18-65. 4. english-speaking patients. exclusion criteria: 1. asa classes iv and v. 2. patients younger than 18 or older than 65. 3. contraindication to regional anesthesia (coagulopathy, patient refusal). 4. allergy to local anesthetic or other study medications. 5. bmi \> 35 kg/m2. 6. chronic opioid use (daily or almost daily use for \> 3 months). 7. active illicit drug use. 8. additional surgical site other than the limb for adductor canal block. 9. pregnancy. 10. preexisting neuropathy in the operative limb. 11. inability to communicate to investigators or hospital staff. 12. inability to speak or understand english.
study to assess the efficacy & safety of khk4951 in patients with neovascular age-related macular degeneration

Conditions: Neovascular Age-Related Macular Degeneration (nAMD)

Summary: the purpose of this study is to evaluate efficacy and safety of khk4951 eye drops in patients with namd.


Eligibility criteria:
inclusion criteria: * voluntary written informed consent to participate in the study * active subfoveal mnv (any subtype) or juxtafoveal/extrafoveal mnv secondary to amd with a subfoveal component related to the mnv activity in the study eye as assessed by fa (evidence of leakage) or sd-oct (presence of fluid) judged by the central reading center at screening * bcva etdrs letter score of 78 letters to 35 letters in the study eye as measured by the etdrs visual acuity chart at screening * cst ≥ 450 μm at screening exclusion criteria: * subretinal hemorrhage, fibrosis, or atrophy of \> 50% of the total lesion area and/or that involves the fovea in the study eye * uncontrolled glaucoma in the study eye * aphakia or pseudophakia with ac-iol in the study eye * active intraocular inflammation in the study eye * any current ocular condition for which visual acuity loss would not improve from resolution of macular edema in the study eye * history of rhegmatogenous retinal detachment in the study eye * any current or history of ocular disease other than namd in the study eye that may confound assessment of the macula or affect central vision * history of the following therapies in the study eye: * history of vitrectomy surgery, submacular surgery, or other surgical intervention for amd * prior treatment pdt with visudyne®, external-beam radiation therapy, transpupillary thermotherapy, or panretinal photocoagulation * periocular or intraocular (sub-tenon or ivt) corticosteroids within 12 weeks prior to day 1 * previous intraocular device implantation except pc-iol * previous laser (any type) to the macular area * previous treatment with ivt anti-vegf drugs other than ranibizumab, bevacizumab, aflibercept 2 mg, and their biosimilars; * treatment with ranibizumab, bevacizumab, aflibercept 2 mg, or their biosimilars within 12 weeks prior to day 1. previously treated patients who received these medications more than 12 weeks prior to day 1 can be enrolled, but the patients should be diagnosed with namd within 3 years prior to day 1 * any current or history of endophthalmitis in either eye * history of idiopathic or autoimmune-associated uveitis in either eye * active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
combination of proton therapy with immunotherapy in multiple metastases cancer

Conditions: Proton Therapy; Immunotherapy; Neoplasm Metastasis

Summary: the purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using proton radiation therapy in combination with immunotherapy(ie. programmed cell death protein 1, also known as pd-1 antibody) in multiple metastases.

as is known to all, the main treatment method for metastatic tumors is systemic chemotherapy and radiotherapy is merely for the purpose of palliative treatment. recent studies have shown that tumors with no more than 5 metastatic sites can still achieve satisfactory overall survival by local treatments such as radiotherapy. however, for tumors with more metastatic lesions, side effect is pretty high for photon radiotherapy due to the wide range of irradiation. protons might be a safe treatment means for multiple metastases cancer because of the brag peak, when the normal tissue dose can be significantly reduced. combination of proton therapy with immunotherapy can be a research direction for multiple metastatic tumors. this study intends to observe the safety and efficacy of proton technique combined with immunotherapy in improving the overall anti- tumor effect for metastatic tumors.

Eligibility criteria:
inclusion criteria: * pathologically confirmed unspecified adult solid tumor * multiple metastatic tumors * intending to be treated with proton beam and immunotherapy * age ≥ 18 years old * kps≥70 * signed written informed consent. exclusion criteria: * pregnant or breastfeeding woman * patient under guardianship or tutorship * patients or legal guardians who are unable to understand informed consent document
the effect of insulin detemir on blood glucose control in taiwanese patients with type 2 diabetes failing on oad

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: the trial is conducted in asia. the aim of the trial is to evaluate the effect of insulin detemir on blood glucose control in taiwanese patients with type 2 diabetes failing on oad with/without once-daily nph insulin treatment.


Eligibility criteria:
inclusion criteria: * type 2 diabetes * hba1c: 7.0-11.0% * previous diabetes treatment for at least 6 months * bmi max. 35 kg/m2 * treatment with an oral anti-diabetic drug (oad) exclusion criteria: * type 1 diabetes * receipt of any investigational drug within the last three months prior to this trial